Long-term clinical control in acromegaly patients with postoperative discordant nadir growth hormone during oral glucose tolerance test and insulin-like growth factor 1 levels: a retrospective observational study and literature review Authors: Tomohisa Ishida, Tomohiro Kawaguchi, Yoshikazu Ogawa, Hidenori Endo Published: 2025 ABSTRACT AbstractBackgroundPostoperative evaluation in patients with acromegaly typically involves measuring insulin-like growth factor 1 (IGF-1) levels and assessing growth hormone (GH) suppression via an oral glucose tolerance test (OGTT). However, discrepancies between these results are not uncommon. Despite this, there are very few studies examining long-term clinical outcomes in patients with persistent discordance between GH nadir and IGF-1 levels. In this study, we focused on such patients and conducted a retrospective analysis to clarify their mid- to long-term outcomes, alongside a review of relevant literature.MethodsWe retrospectively reviewed patients with acromegaly who underwent transsphenoidal resection of pituitary tumors at a single institution and had serial endocrinological evaluations for more than one year between May 2005 and July 2020. Patients were divided into two groups: those with normal GH suppression during OGTT but elevated IGF-1 levels (Group I) and those with abnormal GH suppression but normal IGF-1 levels (Group II) at their 1-year postoperative evaluation. We investigated whether IGF-1 levels normalized or re-elevated over time, alongside monitoring clinical signs and comorbidity management.ResultsDuring the study period, 52 patients who were evaluated by serial IGF-1 and OGTT, 10 demonstrated discordance between GH nadir and IGF-1 levels—3 in Group I and 7 in Group II. In all Group I patients, delayed normalization of IGF-1 was observed, taking 3 to 5 years. No IGF-1 re-elevations occurred, and clinical signs and comorbidities were well controlled. In Group II, abnormal GH suppression during OGTT persisted in all patients; however, IGF-1 levels remained within the normal range without re-elevations. Clinical signs and comorbidities remained clinically stable without the need for additional therapy during the 11-year follow-up period.ConclusionMost patients achieved a mid- to long-term disease-controlled state without additional treatment. Given the potential risk of GH deficiency from further treatment, it may be reasonable to consider patients clinically controlled as long as IGF-1 levels remain normalized, with careful long-term monitoring recommended.Keywords: Acromegaly, Discordant, OGTT, IGF-1, Postoperative, GH Introduction The primary treatment goal of acromegaly is the normalization of excessive growth hormone (GH) secretion, which is typically evaluated through insulin-like growth factor 1 (IGF-1) levels and GH suppression via the oral glucose tolerance test (OGTT) [1, 2]. Although these tests provide complementary information, discrepancies between the results are not uncommon, especially as remission criteria become more stringent [3, 4]. While delayed normalization of IGF-1 levels is well recognized, few studies have investigated the long-term clinical outcomes in patients with persistent discordance between GH nadir and IGF-1 levels. The evidence needed to guide clinical decisions, whether these patients are in a clinically disease-controlled state without additional therapy or at risk of recurrence remains to be established. In this study, we focused on patients with postoperative discordant GH nadir and IGF-1 levels at the 1-year evaluation, conducting a retrospective analysis to clarify their mid- to long-term outcomes. Persistent abnormal GH suppression, which does not meet the criteria for biochemical remission over a prolonged period, may not necessarily be associated with worsened clinical control. Patients and methods Patients We retrospectively reviewed consecutive patients with acromegaly who underwent surgical resection at Kohnan Hospital between May 2005 and July 2020. Acromegaly was diagnosed based on biochemical findings, including elevated serum age- and sex- matched IGF-1 levels relative to the normal range and a GH nadir > 0.4 mg/L during the OGTT, supported by clinical features and the presence of a pituitary tumor on magnetic resonance (MR) imaging. Definitive diagnoses were confirmed by pathological evaluation of surgical specimens. For this study, we included patients who met the following criteria: (1) Patients with IGF-1 levels and OGTT measurements performed at least twice, with the first evaluation at 1 year after surgery and the second at least 1 year later; (2) Patients with normal GH suppression but elevated IGF-1 levels, or abnormal GH suppression but normal IGF-1 levels at the 1-year evaluation. Patients who underwent reoperation or received preoperative treatments such as somatostatin analogs, dopamine agonists, or gamma knife radiosurgery were excluded from the study. All patients underwent transsphenoidal tumor resection under general anesthesia. This study was approved by the institutional review board of Kohnan Hospital. Because this was a retrospective study, the duration of follow-up varied among patients depending on the timing of their individual surgeries during the study period. Importantly, the groups were not defined by surgical era (e.g., before or after a specific year); rather, the difference in follow-up length simply reflects the natural variation in surgical dates. Data collection and measurement Biochemical examinations, including OGTT and IGF-1 levels, were performed in all patients before surgery, at 1 year post-surgery, and at least annually thereafter. For the OGTT, after an overnight fast, blood samples were taken at baseline (fasting) and then at 60, 90, and 120 min after ingestion of 75 g of dextrose. GH was measured using an electro chemiluminescent immunoassay (ECLIA) with a human GH kit (Roche Diagnostic Corporation), in which standardized recombinant GH was employed. IGF-1 was also measured using an IGF-1 kit (Roche Diagnostic Corporation). The reference range for IGF-1 in the normal Japanese population was derived from a previous report [5]. Biochemical remission was defined as the normalization of age- and sex-matched serum IGF-1 levels and GH suppression (GH nadir) to less than 0.4 mg/L during OGTT, according to current consensus guideline [1, 2]. The following variables were recorded in a database: age, sex, tumor size, and Knosp grading. We also investigated clinical signs (arthralgia, hyperhidrosis, paresthesia, and headache), cancer development, cardio- or cerebrovascular events, and control of comorbidities such as hypertension and diabetes mellitus. Evaluation Patients with discordant GH nadir and IGF-1 levels at 1 year post-surgery were divided into two groups for analysis: Group I (normal GH suppression with elevated IGF-1 levels) and Group II (abnormal GH suppression with normal IGF-1 levels). The difference in follow-up periods between the two groups was not intentional; it arose because surgeries were performed at different time points, resulting in variable follow-up durations at the time of analysis. Ten patients with discordant GH nadir and IGF-1 levels at 1 year post-surgery were divided into two groups for analysis: Group I (normal GH suppression with elevated IGF-1 levels) and Group II (abnormal GH suppression with normal IGF-1 levels). During the follow-up period, we assessed whether IGF-1 levels were maintained within the normal range or re-elevated, alongside monitoring clinical signs and comorbidities. The occurrence of mortality, cancer development, and cardio- or cerebrovascular events was also investigated. Results Study participants A flowchart illustrating the patient inclusion and exclusion process is shown in Fig. 1. 52 patients had sufficient endocrinological data in the study. 10 met the remission criteria at 1 year after surgery. On the other hand, 32 patients did not meet the remission criteria with elevated IGF-1 levels and abnormal GH suppression and required additional treatments, such as medical therapy. The 10 patients who showed discordant GH nadir and IGF-1 levels at the 1-year postoperative evaluation and received subsequent serial evaluations were finally included and analyzed in this study. There are many excluded patients because most of these achieved biochemical remission early in the postoperative period and were subsequently evaluated primarily by IGF-1, with normal IGF-1 levels maintained. Flow chart of the current study population IGF-1, insulin-like growth factor-1; OGTT, oral glucose tolerance test Basic characteristics In this study, the 10 patients eligible for analysis were followed for a median of 5 years (range: 2–11 years). The basic characteristics of the enrolled patients, including age, proportion of smaller tumors (< 10 mm), Knosp grade, pathology, and tumor recurrence, are shown in Table 1. Table 1Characteristic of enrolled patients IGF-1: insulin-like growth factor-1, PitNET pituitary neuroendocrine tumorPatients with Discordant (n = 10)Age, range (median)44–75 (56)Female (%)5 (50%)Maximum tumor size with < 10 mm3 (30%)Knosp Grade0–2Gross total removal9(90%)Pathology Somatotroph PitNET6 Somatotroph plurihormonal PitNET4Follow up period, range (median, years)2–11(4.5)Recurrence or regrowth of tumor0Re-elevation of IGF-10 Characteristic of enrolled patients IGF-1: insulin-like growth factor-1, PitNET pituitary neuroendocrine tumor Of the 10 patients, 3 had tumors smaller than 10 mm, while the others had tumors ranging from 10 to 23 mm in diameter. Post operative MR imaging revealed that gross total removal was achieved in all patients except one, and all were observed without additional therapy. At the 1-year postoperative evaluation, 3 patients showed normal GH suppression with elevated IGF-1 levels (Group I), while the remaining 7 showed abnormal GH suppression with normal IGF-1 levels (Group II). Group I patients: normal GH suppression with elevated IGF-1 levels Group I included patients Case 1–3 (Table 2). Preoperative IGF-1 concentrations ranged from 457 to 1,523 ng/mL (1.03–1.27 x upper limit of normal (ULN)), and GH levels ranged from 2.05 to 44.9 ng/mL, with no suppression during OGTT. Post operative MR imaging showed that gross total removal was achieved in 2 cases. In all cases, IGF-1 levels continued to decrease after the 1-year evaluation, eventually falling below the upper limit of the reference range. The time to IGF-1 normalization ranged from 3 to 5 years. During the follow-up period (5–7 years), IGF-1 levels remained within the reference range throughout the follow-up period, with no evidence of re-elevations, even in the case of subtotal removal. Postoperatively, GH nadir levels remained below 0.4 ng/mL in all patients, with no evidence of re-elevation during the follow-up period. No tumor recurrence or regrowth was observed. Clinical signs improved postoperatively and did not recur, with good control of comorbidities. There were no mortalities, cancer, renal failure, hepatic disease or cardio- or cerebrovascular events. In addition, in most patients, antihypertensive and antidiabetic medications could be discontinued or reduced during follow-up, indicating improvement in metabolic sequelae after surgical cure. Table 2Characteristics of postoperative patients with discordant between IGF-1 and GH nadir after OGTTNoGroupAgeSexTumor size(mm)KnospgradeTumor removalCommoditiesPreoperative1 yearlast F/UF/U yearsControl ofcommoditiesIGF-1GH nadirIGF-1GH nadirIGF-1GH nadir1173F10 × 16 × 142SubtotalHT, DM 457 (54–167)not suppressed 212 (53–165)0.32113(46–154) 0.95 6good2153M17 × 15 × 191GTRHT, DM 1523 (85–240)not suppressed 244 (84–239)0.18155(81–235)0.215good3175F16 × 20 × 191GTRHT, DM 573 (52–163)not suppressed 168 (50–160)0.23148(45–152)0.287good4260F6 × 9 × 91GTRDM 377 (71–203)2.02200(70–201) 0.91 155(68–196) 1.12 3good5255F4 × 7 × 70GTRHT 460 (75–210)8.39155(74–208) 0.86 123(72–205) 0.52 3not changed6258M16 × 10 × 91GTRHT 605 (81–23512.3154(80–233) 0.56 116(79–232) 0.43 2good7253M6 × 11 × 101GTRHT 409 (85–240)5.54128(84–239) 1.77 112(82–236) 1.74 4good8244F21 × 17 × 181GTRHT 435 (88–229)27.34158(87–226) 1.20 90(81–218) 2.43 6good9253M23 × 17 × 162GTRnone 1017 (85–240)7.63199(84–239) 1.19 195(84–238) 1.22 2good10251M8 × 4 × 70GTRHT, DM 304 (88–246)2.41243(87–245) 0.98 210(79–232) 1.45 11goodDM diabetes mellitus, F female, F/U follow up, GH growth hormone, GTR gross total removal, HT hypertension, IGF-1 insulin-like growth factor-1, M male, The value of IGF-1 (ng/ml) and GH nadir (ng/ml) demonstrated, and abnormal vale was marked in bold. IGF-1 was demonstrated with ± 2 standard deviation(SD) Characteristics of postoperative patients with discordant between IGF-1 and GH nadir after OGTT 457 (54–167) 212 (53–165) 113 (46–154) 1523 (85–240) 244 (84–239) 155 (81–235) 573 (52–163) 168 (50–160) 148 (45–152) 377 (71–203) 200 (70–201) 155 (68–196) 460 (75–210) 155 (74–208) 123 (72–205) 605 (81–235 154 (80–233) 116 (79–232) 409 (85–240) 128 (84–239) 112 (82–236) 435 (88–229) 158 (87–226) 90 (81–218) 1017 (85–240) 199 (84–239) 195 (84–238) 304 (88–246) 243 (87–245) 210 (79–232) DM diabetes mellitus, F female, F/U follow up, GH growth hormone, GTR gross total removal, HT hypertension, IGF-1 insulin-like growth factor-1, M male, The value of IGF-1 (ng/ml) and GH nadir (ng/ml) demonstrated, and abnormal vale was marked in bold. IGF-1 was demonstrated with ± 2 standard deviation(SD) Group II patients: abnormal GH suppression with normal IGF-1 levels Group II included patients Case 4–10 (Table 2). Preoperative IGF-1 concentrations ranged from 304 to 1,017 ng/mL, and nadir GH levels during OGTT ranged from 2.02 to 27.34 ng/mL. Body mass index (BMI) was ranged 19.3–27.0 kg/m2. There were no patients with low body weight (BMI under 18.5 kg/m2). Gross total removal was achieved in all cases, and no intraoperative cavernous sinus invasion was observed. During the follow-up period (2–11 years), although GH nadir levels remained above 0.4 mg/L in all patients, IGF-1 levels were maintained within the normal range throughout the follow-up period, with no evidence of re-elevations. Clinical symptoms improved early postoperatively and did not recur and no residual tumor or recurrence was visible on MR imaging. Comorbid conditions, such as diabetes mellitus and hypertension, were well controlled, with no clinical deterioration or requirement for additional treatment during follow-up. Illustrative case A 44-year-old woman (Case No. 8 in Table 2) was referred to our hospital with chronic headaches and bitemporal hemianopsia. She had a history of hypertension, sleep apnea, and carpal tunnel syndrome. Elevated serum IGF-1 levels and abnormal GH suppression during OGTT were observed (IGF-1: 435 (normal range: 88–229) ng/mL; basal GH: 32.6 ng/mL; nadir GH: 27.3 ng/mL). Postcontrast T1-weighted MR imaging revealed a suprasellar round mass (Fig. 2A). Transsphenoidal resection of the pituitary tumor was performed, resulting in gross total removal (Fig. 2B). Immunohistochemical analysis revealed a plurihormonal adenoma. The postoperative course was uneventful, with improvements in her chronic headaches and visual disturbances. At the 1-year postoperative evaluation, IGF-1 levels had normalized; however, GH levels remained unsuppressed, staying above 0.4 mg/L during OGTT. Over 6 years of follow-up, abnormal GH suppression persisted, while IGF-1 levels continued to decrease (Fig. 2D). No tumor recurrence was observed on MR imaging (Fig. 2C). Illustrated case (Case No 8 in Table 2). A: Postcontrast T1-weighted magnetic resonance (MR) imaging showed an enhanced suprasellar round mass, compressing optic chiasm. B: Postoperative MR imaging reveals no tumor remnant. C: At the 6-year evaluation post-surgery, no tumor recurrence was observed. D: Summary of biochemical tests, including serum IGF-1 levels, basal serum GH levels, and GH nadir during OGTT. GH, Growth hormone; IGF-1, insulin-like growth factor-1; OGTT, oral glucose tolerance test Discussion This study investigated the mid- to long-term biochemical and clinical outcomes in acromegaly patients with postoperative discordant GH nadir and IGF-1 levels. Our results show that IGF-1 levels in all patients normalized and remained within the normal range without additional treatment, while GH levels also remained suppressed during follow-up. Clinical symptoms and comorbidities were well controlled. In the literature, several authors have reported observational studies that include postoperative discordance, summarized in Table 3 [4, 6–9]. There are two patterns of discordant GH nadir and IGF-1 biochemical status. The first pattern involves normal GH suppression with elevated IGF-1 levels, as seen in Group (I) Delayed normalization of IGF-1 levels is expected under normal GH suppression (i.e., less than 0.4 mg/L), sometimes taking 12 months or more after surgery [10, 11]. Among our 3 cases in Group I, delayed normalization of IGF-1 was observed, even in a case with tumor remnants. In our case, immunohistochemistry revealed a plurihormonal adenoma. Although some studies have suggested that certain histological subtypes, including plurihormonal or sparsely-granulated adenomas, may show delayed biochemical remission, the evidence remains inconclusive. Delayed IGF-1 normalization is likely multifactorial, involving residual tumor activity, GH secretion dynamics, and metabolic factors. In addition, the residual lesion remained unchanged on MR imaging for 7 years and appeared to be endocrinologically and biologically inactive, as no hormonal re-elevation was observed during follow-up. This may suggest partial impairment of the tumor’s vascular supply during surgery, leading to loss of secretory activity rather than size reduction. The second biochemical pattern involves abnormal GH suppression with normal IGF-1 levels, as seen in Group (II) In our series, this pattern was observed in 7 of 52 patients (13.5%), which is generally consistent with previous reports describing an incidence of 5–35.5% among postoperative patients [3, 12]. In a literature review, including our seven cases, a total of 89 patients were categorized into this pattern, with approximately 80% maintaining normal IGF-1 levels. Intraoperative findings of no cavernous sinus invasion and gross total removal have been suggested to correlate with a lower rate of IGF-1 re-elevation [4]. All 7 of our cases achieved gross total removal, and no cavernous sinus invasion was observed intraoperatively. Although discordant biochemical status persisted, IGF-1 levels remained within the normal range for up to 11 years. However, in our review, 15 out of 81 patients showed IGF-1 re-elevation. This indicates that the outcome of this biochemical pattern remains undefined and uncertain, even after many years, due to the potential risk of IGF-1 re-elevation. Nevertheless, in patients without risk factors such as incomplete resection or cavernous sinus invasion, long-term IGF-1 normalization is likely to be expected. Table 3Summary of observational study describing postoperative discordance between IGF-1 and OGTTStudy designDetails of DiscordanceNumber of patientsF/U period(years)Evaluation of IGF-1 at last F/Uclinical symptomRonchi et al. (2007)Retrospectivenormal IGF-1 with GHn > 0.2624 patients3–13All patients: normal rangeNoneBrzana et al. (2012)Retrospectivemild elevated IGF-1 with GHn < 0.413 patients1–510 patients: normal rangeNoneNishioka et al. (2017)Retrospectivenormal IGF-1 with GHn > 0.47 patients4–64 patients: re-elevationN/AGraillon et al. (2020)Retrospectivenormal IGF-1 with GHn > 0.419 patients1.5–1117 patients: normal rangeN/A2 patients: re-elevationN/AFreda et al. (2021)Prospectivenormal IGF-1 with GHn > 0.1424 patients1.9–2216 patients: normal range9 patients: re-elevationnot consistentPresent studyRetrospectiveelevated IGF-1 with GHn < 0.43 patients5–7All patients: normal rangeNonenormal IGF-1 with GHn > 0.47 patients2–11All patients: normal rangeNoneF/U follow up, GH growth hormone, GHn GH nadir, IGF-1 insulin-like growth factor-1, N/A not available, OGTT oral glucose tolerance test Summary of observational study describing postoperative discordance between IGF-1 and OGTT F/U follow up, GH growth hormone, GHn GH nadir, IGF-1 insulin-like growth factor-1, N/A not available, OGTT oral glucose tolerance test The exact reasons for discordant GH nadir and IGF-1 levels are unknown. Certain conditions, including chronic renal failure, chronic hepatitis, hyperthyroidism, type 1 diabetes mellitus, oral estrogen use, alcohol abuse, anorexia nervosa, and GH receptor polymorphism, may induce abnormal GH suppression [13, 14]. It is also suggested that dysregulation of GH secretion persists despite successful treatment of acromegaly, potentially due to disruption of its neural or anatomical systems [15]. Abnormal GH suppression has been shown to cause mild GH excess, as seen through greater mean GH levels during hourly sampling [16]. IGF-1 levels may remain normal if GH secretion is only mildly elevated. In this context, regardless of the cause, it is reasonable to consider the possibility of mild GH excess in patients with discordant results. The most important concern is the clinical outcome resulting from postoperative abnormal GH suppression and mild GH excess. GH suppression during OGTT plays a less clear role in clinical outcomes compared to IGF-1 [1, 2, 12, 17]. In our observational study, disease-associated symptoms and comorbidities (hypertension, diabetes mellitus, heart failure and headache) did not worsen in patients with abnormal GH suppression but normal IGF-1 levels. Previous literature also lacks consistent patterns of worsening signs and symptoms [9]. Although mild GH excess presents a potential risk for IGF-1 re-elevation, there is insufficient evidence to suggest that GH levels need to be suppressed to within the normal range with additional treatment [3, 9]. Further treatment to lower GH levels may increase the risk of GH deficiency [18, 19]. Stricter biochemical control does not always result in more effective clinical control. Given the limited sample size, our findings should be interpreted with caution. However, as long as IGF-1 normalization is maintained, these patients may be considered clinically controlled. In such cases, careful observation with monitoring of IGF-1 and GH levels could be considered reasonable, and additional treatment may not be immediately necessary. Our study has several limitations. First, number of patients is limited. Larger studies are needed to confirm our results. Second, histological diagnosis is heterogenous. In this study, there were 4 patients with somatotroph plurihormonal PitNET, which all were GH/PRL co-producing tumor (PRL levels rage:17.2-114.5 ng/mL). Among them, two were in Group1, the others were in GroupⅡ. Unfortunately, only four cases were available, and no distinctive correlation was observed between histological types and clinical characteristics. Third, the mechanisms underlying why patients may remain asymptomatic despite not meeting postoperative remission criteria is not clear. One possible explanation is the balance between hormone secretion levels and tissue sensitivity. Conclusion In our observation of postoperative acromegaly patients with discordance between GH nadir by OGTT and IGF-1 levels, a mid- to long-term clinically disease-controlled state was achievable without additional treatment. As long as IGF-1 normalization is maintained without clinical symptoms, it may be reasonable to consider these patients as clinically controlled, with meticulous observation recommended rather than additional treatment. Acknowledgements None. Author contributions T.I. and T.K. wrote the main manuscript text, and Y.O. and H.E. made substantial contributions to the study design and data collection. All authors reviewed the manuscript. Funding No extramural funding was used in support of this work. Data availability The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request. Declarations Ethics approval and consent to participate This study was approved by the Ethics Committee of Kohnan Hospital, Sendai, Miyagi, Japan (IRB approval number: 2023-0118-03). Written informed consent to participate in this study was obtained from all participants. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.